# LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

> **NCT07645300** · PHASE2 · NOT_YET_RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 160 (estimated)

## Conditions studied

- Hypertension Treated With Antihypertensive Drugs
- Chronic Kidney Disease, 3B and 4

## Interventions

- **DRUG:** phase 2A Chlorthalidone
- **DRUG:** phase 2A Spironolactone
- **DRUG:** phase 2A Chlorthalidone + Spironolactone
- **DRUG:** phase 2B Chlorthalidone LD + Spironolactone LD

## Key facts

- **NCT ID:** NCT07645300
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2032-03-31
- **Final completion:** 2032-06-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645300, "LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*